Trial Profile
Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients Undergoing Adjuvant Chemotherapy: An Open Label, Randomised, Multi-Centre, Phase IIIb Study.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Goserelin (Primary)
- Indications Female infertility
- Focus Therapeutic Use
- Acronyms PROOF
- Sponsors AstraZeneca
- 09 Dec 2010 Planned end date changed from Jan 2011 to Apr 2012 as reported by ClinicalTrials.gov.
- 18 Aug 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 04 May 2009 New trial record